Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.870
-0.250 (-11.79%)
At close: Mar 28, 2025, 4:00 PM
1.702
-0.168 (-8.98%)
After-hours: Mar 28, 2025, 7:55 PM EDT

Skye Bioscience Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
11.497.712.34.924.34
Upgrade
Research & Development
18.75.826.012.931.94
Upgrade
Other Operating Expenses
0-0---
Upgrade
Operating Expenses
30.1913.5218.317.856.29
Upgrade
Operating Income
-30.19-13.52-18.31-7.85-6.29
Upgrade
Interest Expense
-0.75-0.91-0.67-0.77-0.71
Upgrade
Interest & Investment Income
3.030.10.0200
Upgrade
Other Non Operating Income (Expenses)
---0.06-0.020.44
Upgrade
EBT Excluding Unusual Items
-27.92-14.33-19.02-8.64-6.56
Upgrade
Gain (Loss) on Sale of Assets
1.36-0.31---
Upgrade
Asset Writedown
--0.41-0.46--
Upgrade
Other Unusual Items
--1.38-0.12-
Upgrade
Pretax Income
-26.56-37.64-19.47-8.52-6.56
Upgrade
Income Tax Expense
0.0100.0100
Upgrade
Net Income
-26.57-37.64-19.48-8.52-6.56
Upgrade
Net Income to Common
-26.57-37.64-19.48-8.52-6.56
Upgrade
Shares Outstanding (Basic)
367221
Upgrade
Shares Outstanding (Diluted)
367221
Upgrade
Shares Change (YoY)
420.79%215.43%36.56%75.70%36.48%
Upgrade
EPS (Basic)
-0.73-5.37-8.77-5.24-7.11
Upgrade
EPS (Diluted)
-0.73-5.37-8.77-5.24-7.46
Upgrade
Free Cash Flow
-26.84-13.96-12.84-6.57-6.06
Upgrade
Free Cash Flow Per Share
-0.74-1.99-5.78-4.04-6.55
Upgrade
EBITDA
-29.9-13.4-18.2-7.81-6.29
Upgrade
D&A For EBITDA
0.30.120.110.030
Upgrade
EBIT
-30.19-13.52-18.31-7.85-6.29
Upgrade
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q